A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis
Type of Spiritual Experience
A description of the experience
Dermatoendocrinol. 2013 Jan 1;5(1):222-34. doi: 10.4161/derm.24808. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. Finamor DC1, Sinigaglia-Coimbra R1, Neves LC2, Gutierrez M3, Silva JJ1, Torres LD1, Surano F1, Neto DJ4, Novo NF5, Juliano Y5, Lopes AC6, Coimbra CG1. Laboratório de Fisiopatologia Clínica e Experimental; Universidade Federal de São Paulo; São Paulo, Brazil; Instituto de Ciências da Saúde; Universidade Paulista; São Paulo, Brazil; Farmácia Sensitiva; São Paulo, Brazil; Hospital Heliópolis; São Paulo, Brazil; Disciplina de Cirurgia Plástica; Universidade Federal de São Paulo; São Paulo, Brazil; Disciplina de Clínica Médica; Universidade Federal de São Paulo; São Paulo, Brazil.
Autoimmunity has been associated with vitamin D deficiency and resistance, with gene polymorphisms related to vitamin D metabolism frequently described in affected patients.
High doses of vitamin D3 may conceivably compensate for inherited resistance to its biological effects.
This study aimed to assess the efficacy and safety of prolonged high-dose vitamin D3 treatment of patients with psoriasis and vitiligo.
Nine patients with psoriasis and 16 patients with vitiligo received vitamin D3 35,000 IU once daily for six months in association with a low-calcium diet (avoiding dairy products and calcium-enriched foods like oat, rice or soya "milk") and hydration (minimum 2.5 L daily).
All psoriasis patients were scored according to "Psoriasis Area and Severity Index" (PASI) at baseline and after treatment. Evaluation of clinical response of vitiligo patients required a quartile grading scale.
All patients presented low vitamin D status (serum 25(OH)D3 ≤ 30 ng/mL) at baseline.
After treatment 25(OH)D3 levels significantly increased (from 14.9 ± 7.4 to 106.3 ± 31.9 ng/mL and from 18.4 ± 8.9 to 132.5 ± 37.0 ng/mL) and PTH levels significantly decreased (from 57.8 ± 16.7 to 28.9 ± 8.2 pg/mL and from 55.3 ± 25.0 to 25.4 ± 10.7 pg/mL) in patients with psoriasis and vitiligo respectively. PTH and 25(OH)D3 serum concentrations correlated inversely.
The PASI score significantly improved in all nine patients with psoriasis. Fourteen of 16 patients with vitiligo had 25-75% repigmentation. Serum urea, creatinine and calcium (total and ionized) did not change and urinary calcium excretion increased within the normal range.
High-dose vitamin D3 therapy may be effective and safe for vitiligo and psoriasis patients.